Penserra Capital Management LLC Lowers Stock Holdings in abrdn Life Sciences Investors (NYSE:HQL)

Penserra Capital Management LLC decreased its holdings in shares of abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 9.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 746,921 shares of the company's stock after selling 80,654 shares during the period. Penserra Capital Management LLC owned approximately 2.59% of abrdn Life Sciences Investors worth $9,478,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Commonwealth Equity Services LLC boosted its position in abrdn Life Sciences Investors by 3.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company's stock valued at $395,000 after buying an additional 933 shares during the last quarter. 180 Wealth Advisors LLC boosted its position in abrdn Life Sciences Investors by 0.9% in the first quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company's stock valued at $1,727,000 after buying an additional 1,247 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in abrdn Life Sciences Investors by 379.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company's stock valued at $64,000 after buying an additional 3,847 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in abrdn Life Sciences Investors by 46.5% in the first quarter. Oppenheimer & Co. Inc. now owns 28,713 shares of the company's stock valued at $364,000 after acquiring an additional 9,115 shares during the period. Finally, Wealthcare Advisory Partners LLC acquired a new position in abrdn Life Sciences Investors in the first quarter valued at approximately $131,000. Hedge funds and other institutional investors own 32.21% of the company's stock.

Insider Activity at abrdn Life Sciences Investors

In related news, major shareholder Saba Capital Management, L.P. sold 11,419 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $12.71, for a total value of $145,135.49. Following the completion of the transaction, the insider directly owned 3,017,539 shares of the company's stock, valued at approximately $38,352,920.69. This represents a 0.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 92,544 shares of company stock worth $1,087,994 in the last three months. 10.06% of the stock is currently owned by insiders.

abrdn Life Sciences Investors Trading Up 1.1%

NYSE:HQL traded up $0.15 during trading hours on Tuesday, reaching $13.08. The company had a trading volume of 16,466 shares, compared to its average volume of 107,103. abrdn Life Sciences Investors has a 1-year low of $10.55 and a 1-year high of $15.90. The business's 50 day moving average price is $12.59 and its 200-day moving average price is $12.93.

abrdn Life Sciences Investors Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Thursday, May 22nd were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 13.15%. The ex-dividend date was Thursday, May 22nd.

abrdn Life Sciences Investors Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.